 Home > Active Ingredient News > Antitumor Therapy > Lancet Oncol: The efficacy of pembrolizumab as a single agent in the treatment of BCG-non-responsive high-risk non-muscle invasive bladder cancer

Lancet Oncol: The efficacy of pembrolizumab as a single agent in the treatment of BCG-non-responsive high-risk non-muscle invasive bladder cancer

 Last Update: 2021-05-31
 Source: Internet
 Author: User

Tags

anticholinergic toxicity treatment

muscle invasive bladder cancer

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

The standard treatment for high-risk non-muscle invasive bladder cancer is transurethral bladder tumor resection followed by intravesical BCG immunotherapy .

immunity

The KEYNOTE-057 study evaluated the efficacy and safety of the PD-1 inhibitor pembrolizumab for BCG-non-responsive non-muscle invasive bladder cancer.

This is an open-label, single-arm, multi-center Phase 2 study conducted in 54 medical centers in 14 countries.

From December 9, 2015 to April 1, 2018, a total of 334 patients were screened , of which 186 were not eligible for inclusion, and 47 patients were assigned to cohort B (BCG-non-responsive high Ta stage or no cause Any T1 stage papilloma with cancer; the results were not included in this analysis).

Screening FDA

Duration of response after the first dose of pembrolizumab

The median follow-up was 36.

Of the 96 BCG-non-responsive bladder carcinoma in situ patients with or without papilloma, 39 patients (41%, 95% CI 30.

Treatment-related adverse reactions

Thirteen (13%) patients experienced the most common phase 3/4 treatment-related adverse reactions; the most common were arthralgia (2%) and hyponatremia (3%).

In summary, pembrolizumab is well tolerated as a single-agent treatment of BCG-non-responsive non-muscle invasive bladder cancer, and it has shown promising anti-tumor activity, or it may become such a difficult-to-treat population Non-surgical treatment options .

Pembrolizumab is well tolerated as a single agent in the treatment of BCG-non-responsive non-muscle invasive bladder cancer, and it has shown promising anti-tumor activity, and may be a non-surgical treatment option for this type of difficult-to-treat population Pembrolizumab is well tolerated as a single agent in the treatment of BCG-non-responsive non-muscle invasive bladder cancer, and it has shown promising anti-tumor activity, and may be a non-surgical treatment option for this type of difficult-to-treat population

Original source:

Arjun V Balar, et al.

org/10.
1016/S1470-2045(21)00147-9" target="_blank" rel="noopener">Pembrolizumab monotherapy for the treatment of high- risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study

in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.